SYT-510

Phase 2Small molecule

SSynendos Therapeutics AG

SYT-510 is one of 37 small molecule programs targeting Generalized Anxiety Disorder. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Generalized Anxiety DisorderActive, not recruiting

Generalized Anxiety DisorderPhase 2

Active, not recruiting

Competition

Competitive Landscape

82 competitors in Generalized Anxiety Disorder

#DrugCompanyPhaseTrials

Brintellix

Takeda

Phase 3

4 2

Viibryd

AbbVie

Phase 3

2 3

Seroquel

EEngelhard Arzneimittel GmbH & Co.KG

Phase 3

5 4

PD 0360324

Pfizer

Phase 3

7 5

Risperdal

WWim Janssens

Phase 3

2 6

Effexor

WWyeth-Lederle Vaccines

Phase 3

2 7

Quetiapine XR

AstraZeneca

Phase 3

2 8

Lu AF95245

Lundbeck

Phase 3

1 9

Vraylar

AbbVie

Phase 2

1 10

Venlafaxine XR

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

Phase 2Not yet recruiting

Generalized Anxiety Disorder

NCT07478744

Clinical

Trials by Indication[1]

Generalized Anxiety Disorder1 trial

A Phase 2a Efficacy, Safety, Tolerability, and PK Study of SYT-510 in Participants With Generalized Anxiety Disorder

Not yet recruiting·SSynendos Therapeutics AG·Phase 2·NCT07478744·24 enrolled

Single Dose1 trial

A Phase 1 Single Dose and Multiple Ascending Dose Study to Assess the Relative Bioavailability, Food Effect, Safety, Tolerability and Pharmacokinetics of SYT-510 in Healthy Participants

Recruiting·SSynendos Therapeutics AG·Phase 1·NCT06670950·90 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for SYT-510. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — SYT-510 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for SYT-510. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Synendos Therapeutics AG company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: SSynendos Therapeutics AG

SYT-510

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2027

Trials by Indication[1]

Generalized Anxiety Disorder1 trial

Single Dose1 trial

References

Drug Info

Quick Facts

Related News